News & Events

Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022

Halle (Saale) / Munich, Germany, May 11, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon; or the Company), a clinical stage company focused on discovery and development of […]

Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress

Substantial progress in clinical development of QPCT/L inhibitor varoglutamstat, EU and U.S. clinical studies in AD on track FDA Fast Track designation for lead product candidate […]

Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022

Halle (Saale) / Munich, Germany, April 21, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]

Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences

HALLE (SAALE) / MUNICH, GERMANY, April 20, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]

Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 21 Million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. Halle (Saale) / Munich, Germany, April […]

Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. Halle (Saale) / Munich, Germany, March […]

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference

HALLE (SAALE) / MUNICH, GERMANY, March 7, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]

Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer’s Disease

Halle (Saale) / Munich, Germany and Nanjing, China, February 28, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines and […]

Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences

HALLE (SAALE) / MUNICH, GERMANY, January 4, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]